SAG
NTLA icon

SageView Advisory Group’s Intellia Therapeutics NTLA Stock Holding History

SageView Advisory Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,345
Closed -$854K – 670
2024
Q1 		$854K Buy
+19,345
New +$537K 0.04% 222

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SageView Advisory Group's NTLA Position: Q2 2024 in Review

SageView Advisory Group sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 19,345 shares — an estimated $854K sold.

SageView Advisory Group first reported a position in NTLA in Q1 2024 and held it in 1 quarter. The position peaked at $854K in Q1 2024. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

  • SageView Advisory Group reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SageView Advisory Group sold 19,345 Intellia Therapeutics shares in Q2 2024, an estimated $854K.
  • SageView Advisory Group first reported a position in Intellia Therapeutics in Q1 2024 and held it in 1 quarter.
  • SageView Advisory Group's Intellia Therapeutics position peaked at $854K in Q1 2024.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on SageView Advisory Group's 13F filing for Q2 2024, filed 12 Aug 2024.